1XPBS, 1% BSA, 20% Glycerol (pH7). 0.025% ProClin 300 was added as a preservative.
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
0.25 mg/ml (Please refer to the vial label for the specific concentration.)
Recombinant protein encompassing a sequence within the N-terminus region of human LTBP4. The exact sequence is proprietary.
Purified by antigen-affinity chromatography.
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
latent transforming growth factor beta binding protein 4 , ARCL1C , LTBP-4 , LTBP4L , LTBP4S
Secreted , extracellular space , extracellular matrix
Transforming growth factor-beta, or TGFB (see TGFB1; MIM 190180), remains biologically latent after secretion, blocked from activity by its N-terminal propeptide (the latency-associated peptide, or LAP). TGFB is activated by its dissociation from LAP. The latent form of TGFB is secreted in association with a latent TGFB-binding protein, or LTBP (see LTBP1; MIM 150390), and assembled into the extracellular matrix. LTBPs are mainly composed of epidermal growth factor (EGF; MIM 131530)-like repeats and protein domains with 8-cysteine repeats, both of which are also found in fibrillins (e.g., MIM 134797). See Oklu and Hesketh (2000) [PubMed 11104663] for a review of the LTBP gene family.[supplied by OMIM]